{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:46:48Z","timestamp":1790786808187,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005145","name":"Basic Research Program of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20191080"],"award-info":[{"award-number":["BK20191080"]}],"id":[{"id":"10.13039\/501100005145","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81901883"],"award-info":[{"award-number":["No. 81901883"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chimeric antigen receptor T-cell immunotherapy (CAR-T) has shown remarkable efficacy in treating tumors of lymphopoietic origin. Herein, we demonstrate an effective CAR-T cell treatment for recurrent and malignant CD30-positive peripheral T-cell lymphomas (PTCL) has been demonstrated. The extracellular fragment gene sequences of CD30 were obtained from tumor tissues of PTCL patients and cloned into a plasmid vector to express the CD30 antigen. The CD30 targeting single-chain antibody fragment (scFv) was obtained from CD30-positive monoclonal hybridoma cells, which were obtained from CD30 antigen immunized mice. After a second-generation of CAR lentiviral construction, CD30 CAR T cells were produced and used to determine the cytotoxicity of this construct toward Karpas 299 cells. The results of CD30 CAR T-mediated cell lysis show that 9C11-2 CAR T cells could significantly promote the lysis of CD30-positive Karpas 299 cells in both LDH and real-time cell electronic sensing (RTCA) assays. In vivo data show that 9C11-2 CAR T cells effectively suppress the tumor growth in a Karpas 299 cell xenograft NCG mouse model. The CD30 CAR T cells exhibited an efficient cytotoxic effect after being co-cultured with the target cells and they also exhibited a significant tumor-inhibiting ability after being intravenously injected into PTCL xenograft tumors; these observations suggest that the new CD30 CAR-T cell may be a promising therapeutic candidate for cancer therapy.<\/jats:p>","DOI":"10.1038\/s41417-021-00295-8","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T15:02:41Z","timestamp":1611932561000},"page":"167-177","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb"],"prefix":"10.1038","volume":"29","author":[{"given":"Yang","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Chen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-yan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-qiu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Feng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Zhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,29]]},"reference":[{"key":"295_CR1","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1182\/blood-2017-11-817734","volume":"131","author":"JM Vose","year":"2018","unstructured":"Vose JM. Peripheral T-cell lymphoma: novel backbone. Blood. 2018;131:375\u20136.","journal-title":"Blood"},{"key":"295_CR2","doi-asserted-by":"publisher","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","volume":"117","author":"FM Foss","year":"2011","unstructured":"Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood. 2011;117:6756\u201367.","journal-title":"Blood"},{"key":"295_CR3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1309\/AJCP7YLTQPUSDQ5C","volume":"138","author":"J Sun","year":"2012","unstructured":"Sun J, Yang Q, Lu Z, He M, Gao L, Zhu M, et al. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol. 2012;138:429\u201334.","journal-title":"Am J Clin Pathol"},{"key":"295_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1746-1596-6-77","volume":"6","author":"QP Yang","year":"2011","unstructured":"Yang QP, Zhang WY, Yu JB, Zhao S, Xu H, Wang WY, et al. Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution. Diagn Pathol. 2011;6:77.","journal-title":"Diagn Pathol"},{"key":"295_CR5","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1177\/0300060516676725","volume":"45","author":"X Han","year":"2017","unstructured":"Han X, Zhang W, Zhou D, Ruan J, Duan M, Zhu T, et al. Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: a single-centre experience. J Int Med Res. 2017;45:290\u2013302.","journal-title":"J Int Med Res"},{"key":"295_CR6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.blre.2007.03.001","volume":"21","author":"KJ Savage","year":"2007","unstructured":"Savage KJ. Peripheral T-cell lymphomas. Blood Rev. 2007;21:201\u201316.","journal-title":"Blood Rev"},{"key":"295_CR7","first-page":"e74","volume":"32","author":"NPC Zing","year":"2018","unstructured":"Zing NPC, Fischer T, Zain J, Federico M, Rosen ST. Peripheral T-cell lymphomas: incorporating new developments in diagnostics, prognostication, and treatment into clinical practice\u2014PART 1: PTCL-NOS, FTCL, AITL, ALCL. Oncology. 2018;32:e74\u2013e82.","journal-title":"Oncology"},{"key":"295_CR8","doi-asserted-by":"publisher","first-page":"e337","DOI":"10.1016\/j.clml.2019.03.031","volume":"19","author":"M Morita-Fujita","year":"2019","unstructured":"Morita-Fujita M, Katoh D, Shimomura Y, Ishikawa T. High level of serum soluble interleukin-2 receptor is associated with poor survival in patients with first relapsed or refractory peripheral T-cell lymphoma, not otherwise specified: a retrospective study. Cllymph Myelom Leuk. 2019;19:e337\u2013342.","journal-title":"Cllymph Myelom Leuk"},{"key":"295_CR9","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s11899-015-0289-7","volume":"10","author":"M Sakata-Yanagimoto","year":"2015","unstructured":"Sakata-Yanagimoto M, Chiba S. Molecular pathogenesis of peripheral T cell lymphoma. Curr Hematol Malig Rep. 2015;10:429\u201337.","journal-title":"Curr Hematol Malig Rep"},{"key":"295_CR10","doi-asserted-by":"publisher","first-page":"623924","DOI":"10.5402\/2011\/623924","volume":"2011","author":"AN Abouyabis","year":"2011","unstructured":"Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. Systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol. 2011;2011:623924.","journal-title":"ISRN Hematol"},{"key":"295_CR11","first-page":"545","volume":"29","author":"MA Lunning","year":"2015","unstructured":"Lunning MA. Treatment of peripheral T-cell lymphoma: many shades of gray. Oncology. 2015;29:545\u201350.","journal-title":"Oncology"},{"key":"295_CR12","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/s41417-020-0176-9","volume":"12","author":"J Wenthe","year":"2020","unstructured":"Wenthe J, Naseri S, Hellstr\u00f6m A-C, Wiklund HJ, Eriksson E, Loskog A. Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and\/or CD40. Cancer Gene Ther. 2020;12:948\u201359.","journal-title":"Cancer Gene Ther"},{"key":"295_CR13","doi-asserted-by":"publisher","unstructured":"Tay RE, Richardson EK, Toh HC: Revisiting the role of CD4+ T cells in cancer immunotherapy\u2014new insights into old paradigms. Cancer Gene Ther. 2020. https:\/\/doi.org\/10.1038\/s41417-020-0183-x.","DOI":"10.1038\/s41417-020-0183-x"},{"key":"295_CR14","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41417-019-0157-z","volume":"27","author":"MM Papathanasiou","year":"2020","unstructured":"Papathanasiou MM, Stamatis C, Lakelin M, Farid S, Titchener-Hooker N, Shah N. Autologous CAR T-cell therapies supply chain: challenges and opportunities? Cancer Gene Ther. 2020;27:799\u2013809.","journal-title":"Cancer Gene Ther"},{"key":"295_CR15","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s41417-019-0155-1","volume":"27","author":"LF Chai","year":"2020","unstructured":"Chai LF, Prince E, Pillarisetty VG, Katz SC. Challenges in assessing solid tumor responses to immunotherapy. Cancer Gene Ther. 2020;27:528\u201338.","journal-title":"Cancer Gene Ther"},{"key":"295_CR16","doi-asserted-by":"publisher","first-page":"29843","DOI":"10.18632\/oncotarget.25688","volume":"9","author":"A Quintas-Cardama","year":"2018","unstructured":"Quintas-Cardama A. CD19 directed CAR T cell therapy in diffuse large B-cell lymphoma. Oncotarget. 2018;9:29843\u20134.","journal-title":"Oncotarget"},{"key":"295_CR17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1182\/blood-2018-04-839217","volume":"132","author":"VA Chow","year":"2018","unstructured":"Chow VA, Shadman M, Gopal AK. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed\/refractory diffuse large B-cell lymphoma. Blood. 2018;132:777\u201381.","journal-title":"Blood"},{"key":"295_CR18","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMc1704610","volume":"377","author":"JS Abramson","year":"2017","unstructured":"Abramson JS, McGree B, Noyes S, Plummer S, Wong C, Chen YB, et al. Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma. N. Engl J Med. 2017;377:783\u20134.","journal-title":"N. Engl J Med"},{"key":"295_CR19","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMc1704610","volume":"377","author":"JS Abramson","year":"2017","unstructured":"Abramson JS, Chen YB. More on anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma. N. Engl J Med. 2017;377:2102.","journal-title":"N. Engl J Med"},{"key":"295_CR20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1158\/2326-6066.CIR-14-0114","volume":"3","author":"Y Chu","year":"2015","unstructured":"Chu Y, Hochberg J, Yahr A, Ayello J, van de Ven C, Barth M, et al. Targeting CD20+ aggressive B-cell non-Hodgkin lymphoma by anti-CD20 CAR mRNA-modified expanded natural killer cells in vitro and in NSG mice. Cancer Immunol Res. 2015;3:333\u201344.","journal-title":"Cancer Immunol Res"},{"key":"295_CR21","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","volume":"24","author":"P Went","year":"2006","unstructured":"Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24:2472\u20139.","journal-title":"J Clin Oncol"},{"key":"295_CR22","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.3324\/haematol.2012.081935","volume":"98","author":"B Bisig","year":"2013","unstructured":"Bisig B, de Reynies A, Bonnet C, Sujobert P, Rickman DS, Marafioti T, et al. CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features. Haematologica. 2013;98:1250\u20138.","journal-title":"Haematologica"},{"key":"295_CR23","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","volume":"124","author":"C Bossard","year":"2014","unstructured":"Bossard C, Dobay MP, Parrens M, Lamant L, Missiaglia E, Haioun C, et al. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. Blood. 2014;124:2983\u20136.","journal-title":"Blood"},{"key":"295_CR24","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1365-2141.2009.07740.x","volume":"146","author":"A Forero-Torres","year":"2009","unstructured":"Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL, et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Brit J Haematol. 2009;146:171\u20139.","journal-title":"Brit J Haematol"},{"key":"295_CR25","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1200\/JCO.2006.07.8972","volume":"25","author":"SM Ansell","year":"2007","unstructured":"Ansell SM, Horwitz SM, Engert A, Khan KD, Lin T, Strair R, et al. Phase I\/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin\u2019s lymphoma and anaplastic large-cell lymphoma. J Clin Oncol. 2007;25:2764\u20139.","journal-title":"J Clin Oncol"},{"key":"295_CR26","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","volume":"102","author":"JA Francisco","year":"2003","unstructured":"Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102:1458\u201365.","journal-title":"Blood"},{"key":"295_CR27","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1182\/blood-2007-07-099317","volume":"111","author":"NL Bartlett","year":"2008","unstructured":"Bartlett NL, Younes A, Carabasi MH, Forero A, Rosenblatt JD, Leonard JP, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood. 2008;111:1848\u201354.","journal-title":"Blood"},{"key":"295_CR28","first-page":"1116","volume":"58","author":"A Hombach","year":"1998","unstructured":"Hombach A, Heuser C, Sircar R, Tillmann T, Diehl V, Pohl C, et al. An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin\u2019s lymphoma cells in the presence of soluble CD30. Cancer Res. 1998;58:1116\u20139.","journal-title":"Cancer Res"},{"key":"295_CR29","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1182\/blood-2013-12-516245","volume":"123","author":"AJ Moskowitz","year":"2014","unstructured":"Moskowitz AJ, Lunning MA, Horwitz SM. How I treat the peripheral T-cell lymphomas. Blood. 2014;123:2636\u201344.","journal-title":"Blood"},{"key":"295_CR30","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1182\/blood-2016-08-692566","volume":"129","author":"A Broccoli","year":"2017","unstructured":"Broccoli A, Zinzani PL. Peripheral T-cell lymphoma, not otherwise specified. Blood. 2017;129:1103\u201312.","journal-title":"Blood"},{"key":"295_CR31","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 1989;86:10024\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"295_CR32","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.beha.2018.07.011","volume":"31","author":"R Nair","year":"2018","unstructured":"Nair R, Neelapu SS. The promise of CAR T-cell therapy in aggressive B-cell lymphoma. Best Pract Res Clin Haematol. 2018;31:293\u20138.","journal-title":"Best Pract Res Clin Haematol"},{"key":"295_CR33","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1182\/blood.2019000888","volume":"133","author":"P Strati","year":"2019","unstructured":"Strati P, Nastoupil LJ, Fayad LE, Samaniego F, Adkins S, Neelapu SS. Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection. Blood. 2019;133:2800\u20132.","journal-title":"Blood"},{"key":"295_CR34","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol. 2012;30:2183\u20139.","journal-title":"J Clin Oncol"},{"key":"295_CR35","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","volume":"30","author":"B Pro","year":"2012","unstructured":"Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30:2190\u20136.","journal-title":"J Clin Oncol"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-021-00295-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-021-00295-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-021-00295-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:05:11Z","timestamp":1645056311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-021-00295-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,29]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["295"],"URL":"https:\/\/doi.org\/10.1038\/s41417-021-00295-8","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,29]]},"assertion":[{"value":"15 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}